Ipamorelin vs Sermorelin
Reviewed by the BestHealingPeptides Editorial Team ·
Ipamorelin and sermorelin are the two most-studied GH-axis research peptides, but they activate the pituitary GH-release machinery through fundamentally different receptors. Ipamorelin is a GHRP-class compound acting on the ghrelin receptor (GHSR-1a); sermorelin is the prototype GHRH analogue acting on the GHRH receptor. The combination of one of each — the canonical 'sermorelin + ipamorelin' or 'CJC-1295 + ipamorelin' research protocols — exploits the synergy of dual-pathway pituitary activation that defines modern GH-secretagogue research.
Ipamorelin
A pentapeptide GHRP (growth-hormone-releasing peptide) developed by Novo Nordisk in the 1990s, acting as a selective agonist of the GHSR (ghrelin receptor) on pituitary somatotrophs. Distinguished from other GHRP-class compounds by its high GH selectivity — minimal effects on cortisol, prolactin, ACTH, or aldosterone — making it the cleanest GHRP-class research tool when GH-pulse isolation is the experimental goal.
Sermorelin
The first 29 amino acids of native human GHRH — the biologically active N-terminal fragment retaining full GHRH-receptor agonism. The prototype GHRH analogue; formerly licensed as Geref by Serono for paediatric growth-hormone deficiency diagnostic testing. Short half-life (~5-12 minutes) and pulsatile-preserving GH-release pattern make it the classical GH-axis research probe.
| Aspect | Ipamorelin | Sermorelin |
|---|---|---|
| Mechanism class | GHRP-class GHSR-1a (ghrelin receptor) agonist | GHRH-class GHRH-receptor agonist |
| Receptor signalling | Gαq/11 / PLC / IP₃ / Ca²⁺ | Gαs / adenylate cyclase / cAMP / PKA |
| Selectivity | GH only — no cortisol, prolactin, ACTH spillover (unique within GHRP class) | GH only — intrinsic GHRH selectivity |
| Plasma half-life | ~2 hour biological action | ~5-12 minutes |
| Clinical history | Phase I/early Phase II; never licensed | FDA-approved as Geref 1990-2008; discontinued commercially |
| Combination role | GHRP component of the dual-pathway protocol | GHRH component of the dual-pathway protocol |
| WADA status | S2 (peptide hormones / growth factors) | S2 (peptide hormones / growth factors) |
Receptor and signalling — distinct pituitary mechanisms
Sermorelin is the synthetic 29-amino-acid N-terminal fragment of native human GHRH, binding the GHRH receptor (a class B G-protein-coupled receptor) on anterior-pituitary somatotrophs. Activation triggers Gαs/adenylate cyclase signalling, raising intracellular cAMP and driving GH gene transcription and vesicular release via PKA-mediated CREB phosphorylation. Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) acting as a selective full agonist at the growth-hormone secretagogue receptor (GHSR-1a, the ghrelin receptor) — a distinct class A G-protein-coupled receptor coupled to Gαq/11. Activation triggers phospholipase Cβ signalling, generating IP₃ that releases intracellular calcium and diacylglycerol that activates PKC. The two receptors converge on growth-hormone vesicle exocytosis through different intracellular signalling cascades, which is the mechanistic basis of their synergistic combination.
Selectivity profile — the key practical difference
Sermorelin and ipamorelin both produce dose-dependent GH release. The principal pharmacological difference is selectivity for GH release over other anterior-pituitary effects. Sermorelin is intrinsically GH-selective — GHRH receptor activation drives almost exclusively GH release without measurable effects on ACTH, prolactin, cortisol, or other pituitary hormones. Ipamorelin within the GHRP class is uniquely selective: alone among the GHRPs (GHRP-2, GHRP-6, hexarelin), ipamorelin produces no measurable elevation of cortisol, ACTH, prolactin, aldosterone, or FSH at GH-stimulating doses (Raun et al., Eur J Endocrinol, 1998). This selectivity is the principal reason ipamorelin is the GHRP of choice for research where GH-axis isolation is required, and the foundation of the 'sermorelin + ipamorelin' research-chemical-community protocol's clean GH-axis profile.
Evidence depth and clinical history
Sermorelin has the larger clinical-trial evidence base, accumulated through the Geref (Serono) clinical-development programme from approximately 1985 to 2008, including FDA approval for paediatric GH-deficiency diagnostic testing and treatment from 1990 to 2008. Multi-year paediatric therapeutic use produced extensive safety data. Ipamorelin's clinical experience is more limited — Phase I and early Phase II programmes by Novo Nordisk in the late 1990s and 2000s established the favourable acute safety profile and characteristic selectivity, but the compound did not progress to Phase III registration. Both compounds are currently unlicensed in any jurisdiction, with sermorelin's Geref discontinuation in 2008 returning it to unlicensed status.
Pharmacokinetics and dosing — both short-acting
Sermorelin has the shortest plasma half-life of any GHRH-analogue compound at ~5-12 minutes, reflecting rapid DPP-4-mediated cleavage of the N-terminal His-Ala bond. Ipamorelin has a longer ~2-hour effective biological action through GHSR-1a binding. Both compounds preserve pulsatile GH-release patterns rather than producing the sustained elevation of DAC-modified CJC-1295. Both are administered subcutaneously in research; both can be co-administered in the same injection for combination protocols. The shorter sermorelin half-life makes multiple daily administrations more pharmacologically rational; ipamorelin's longer biological action allows fewer daily administrations.
Combination protocol — exploiting dual-pathway synergy
Combined administration of sermorelin and ipamorelin (or the protease-stabilised sermorelin analogue CJC-1295 no-DAC with ipamorelin) produces GH pulses materially larger than either monotherapy through dual-pathway pituitary activation. The GHRH-receptor activation by sermorelin (Gαs/cAMP) plus GHSR ghrelin-receptor activation by ipamorelin (Gq/PLC/calcium) plus somatostatin-tone suppression by GHSR-1a-mediated signalling converge to produce synergistic somatotroph activation. This is the canonical research-chemical-community protocol for maximising pulsatile GH release. The two peptides are pharmacologically complementary, not redundant — combining two GHRH analogues (sermorelin + CJC-1295) or two GHRPs (ipamorelin + GHRP-2) is redundant; combining one of each is synergistic.
Verdict
Sermorelin and ipamorelin are mechanistically complementary GH-axis peptides operating through distinct pituitary receptors. For monotherapy use, sermorelin has the deeper clinical-trial safety record from the Geref era; ipamorelin has the cleanest selectivity profile. For most research applications the canonical combination — sermorelin + ipamorelin, or CJC-1295 no-DAC + ipamorelin — is the pharmacologically rational choice, exploiting dual-pathway pituitary activation for synergistic GH release with preserved pulsatility.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.